Test the efficacy of its compound in a mouse model of KD
Reward amount $100,000. Nathan Beckouche, Phd. Atmos R - Institute of Psychiatry and Neurosciences of Paris,
Summary Description
AtmosR is a Paris-based biotech company specializing in the development of treatments for rare neurological diseases. AtmosR is developing ATS-033, a therapeutic able to destroy the pathological aggregates caused by the gene mutation responsible for Kennedy’s disease. Thanks to the support of the KDA, AtmosR will test the efficacy of its compound in a mouse model of KD, focusing on the motor symptoms of the animals, in order to assess its interest for KD patients.
Bio
Dr. Nathan Beckouche is the Chief Scientific Officer at AtmosR, where he leads groundbreaking research in rare neurological disorders. He holds a Ph.D. in Physiology and Physiopathology from the Pierre and Marie Curie University (Paris), which he followed as a postdoctoral fellow at University Of California San Francisco, which revolved around mouse genetics and disease modeling. He began his industry career at Alexion Pharmaceuticals, focusing on rare diseases in the field of nephrology. His passion for addressing unmet medical needs has driven his transition to neurological disorders, and he started working with the french patient organization for Ondine syndrome, a rare neurodevelopmental disease. He co-founded AtmosR where he leverages his expertise to develop innovative therapies for diseases with high-unmet medical needs, with a team of passionate scientists with complementary profiles.
